Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT142 in CLDN6-positive advanced solid tumors
NL-OMON53910Phase 2Not yet recruiting
- Sponsor
- BioNTech SE
- Start
- Aug 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of BNT142 in Nonhematologic neoplasms, ovarian cancer, non-small cell lung cancer (NSCLC) and 3 more (4 arms), sponsored by BioNTech SE. Primary endpoints: Treatment-emergent adverse events, Dose reductions and discontinuations due to TEAEs and 3 more. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
BNT142
03
Conditions
Nonhematologic neoplasmsovarian cancernon-small cell lung cancer (NSCLC)endometrial cancer (EC)testicular cancer
Beyond the preview
Go deeper on NL-OMON53910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53910.